SCHEMBL3409909

SCHEMBL3409909

CN(CCCN1CCC(c2ccccc2)(N(C)C)CC1)C(=O)Cc1c[nH]c2ccc(Br)cc12

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 5/20 0.48
SIGMAR1 Q99720 1/20 0.45
BCHE P06276 1/20 0.42
ACHE P22303 1/20 0.42
UTS2R Q9UKP6 1/20 0.42
DRD2 P14416 2/20 0.41
DRD3 P35462 2/20 0.41
SLC6A4 P31645 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
OPRM1 P35372 3/20 0.40
OPRL1 P41146 3/20 0.40
TACR2 P21452 1/20 0.39
DRD4 P21917 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3405510 0.85 OPRM1 (0.43) HTR1ASIGMAR1ACHEDRD2SLC6A4
SCHEMBL3406233 0.84 UTS2R (0.45) HTR1ASIGMAR1BCHEACHEUTS2R
SCHEMBL4092770 0.81 NPC1 (0.56) HTR1ADRD2DRD3SLC6A4OPRM1
SCHEMBL27854001 0.81 SIGMAR1 (0.42) HTR1ASIGMAR1BCHEACHEUTS2R
SCHEMBL4099911 0.81 OPRL1 (0.51) HTR1ASIGMAR1BCHEACHEDRD2
SCHEMBL3401797 0.79 OPRM1 (0.44) SIGMAR1ACHEDRD2DRD3OPRM1
SCHEMBL3404187 0.78 SIGMAR1 (0.42) HTR1ASIGMAR1BCHEACHEUTS2R
SCHEMBL3409873 0.76 OPRL1 (0.42) OPRM1OPRL1TACR2MEN1KMT2A
SCHEMBL3405562 0.76 CDK4 (0.57) HTR1AHTR1BOPRM1OPRL1TACR2
SCHEMBL3409859 0.75 OPRL1 (0.41) OPRM1OPRL1TACR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206156-B2 Substituted indole derivatives Grünenthal GmbH (DE) 2015-12-08 US claimed
EP-2254883-B1 SUBSTITUTED INDOLE DERIVATIVES GRUENENTHAL GMBH (DE) 2014-11-26 EP claimed
US-20130116283-A1 Substituted indole derivatives Grünenthal GmbH (DE) 2013-05-09 US claimed
EP-2254883-A1 SUBSTITUTED INDOLE DERIVATIVES Grünenthal GmbH (DE) 2010-12-01 EP claimed
WO-2009103552-A1 SUBSTITUTED INDOLE DERIVATIVES Grünenthal GmbH (DE) 2009-08-27 WO claimed
US-20090215828-A1 Substituted indole derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US claimed
US-9206156-B2 Substituted indole derivatives Grünenthal GmbH (DE) 2015-12-08 US disclosed
US-9206156-B2 Substituted indole derivatives Grünenthal GmbH (DE) 2015-12-08 US disclosed
EP-2254883-B1 SUBSTITUTED INDOLE DERIVATIVES GRUENENTHAL GMBH (DE) 2014-11-26 EP disclosed
EP-2254883-B1 SUBSTITUTED INDOLE DERIVATIVES GRUENENTHAL GMBH (DE) 2014-11-26 EP disclosed
US-20130116283-A1 Substituted indole derivatives Grünenthal GmbH (DE) 2013-05-09 US disclosed
US-20130116283-A1 Substituted indole derivatives Grünenthal GmbH (DE) 2013-05-09 US disclosed
US-20090215828-A1 Substituted indole derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US disclosed
US-20090215828-A1 Substituted indole derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US disclosed
US-20090215828-A1 Substituted indole derivatives GRUNENTHAL GMBH (DE) 2009-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215828-A1 Substituted indole derivatives IDO1, IDO2, TPH1 HTR1A 19/4885SIGMAR1 235/4885BCHE 2840/4885
US-20130116283-A1 Substituted indole derivatives IDO1, IDO2, TPH1 HTR1A 19/4885SIGMAR1 235/4885BCHE 2840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.